Intensity-Modulated Radiation Therapy Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Arytenoid-Sparing Intensity-Modulated Radiotherapy for Early-Stage Glottic Cancer
In this study, we demonstrate initial dosimetric results of a novel approach called arytenoid-sparing IMRT (AS-IMRT), which is aimed at reducing speech and swallowing toxicity. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: A. Rybkin, J. Scott, M.R. Young, H.S.M. Park Tags: 129 Source Type: research

Tubarial Gland Sparing with Intensity-Modulated Radiation Therapy for Oropharyngeal Cancers: A Pilot Study of Dosimetric Feasibility
In this study, we hypothesized that intensity-modulated radiation therapy (IMRT), which is widely utilized in the treatment of oropharyngeal carcinoma, would reduce the mean dose to the tubarial glands without a significant difference in target coverage. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: N.S. Kalman, S. Yarlagadda, N. McAllister, A.E. Rzepczynski, T. Kutuk Tags: 120 Source Type: research

Outcomes in Patients with Oral Cavity Squamous Cell Carcinomas with Respect to Initiation of Chemotherapy and Adjuvant IMRT Timing
Patients with advanced oral cavity squamous cell carcinoma (OCSCC) have high recurrence rates. The current treatment paradigm consists of definitive surgery followed by risk-adapted adjuvant radiation therapy (RT) with or without concurrent chemotherapy. We hypothesized that initiating chemotherapy on the same day as RT and shorter interval between surgery and starting RT would improve oncological outcomes. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: K.R. Cargill, J.A.A. Vargo, U. Iheagwara, S. Kim, M.W. Kubik, S. Sridharan, U. Duvvuri, D.P. Zandberg, Z. Rahman, R. Seethala, J.P. Zevallos, R. Ferris, H.D. Skinner, Y.M. Mowery, C.T. Wilke Tags: 117 Source Type: research

Two-Year Intention-to-Treat Analysis for Tumor Outcome in Patients Treated with Avasopasem for Oral Cavity and Oral Pharynx Primaries
IMRT plus cisplatin (CRT) is established treatment for LAHNC, but ∼70% of patients develop severe oral mucositis (SOM), often requiring feeding tube nutrition. Avasopasem (AVA) is an investigational small molecule selective dismutase mimetic converting superoxide to hydrogen peroxide, which may protect normal cells from, and potentially sensitize cancer cells to , RT (Anderson 2019, Sishc 2021). In a randomized, double-blind phase 3 trial, AVA substantially reduced duration and incidence of SOM versus placebo (PBO) without an adverse effect on safety or 1-yr survival (Anderson 2022). (Source: International Journal of Rad...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: N.E. Dunlap, C.M. Lee, J.R. Kelley, G.V. Walker, V. Bar-Ad, D.A. Miller, V.J. King Sr, A.V. Peddada, D. Ciuba, F. Vincent, B.C. Muzyka, A.L. Gillespie-Twardy, S.T. Sonis, J. Holmlund, D. Saunders, R. Beardsley, C.M. Anderson Tags: 11 Source Type: research

Generalized Pairwise Comparisons Method to Assess Total Severe Oral Mucositis Burden and Interventional Benefit in HNC
Severe oral mucositis (SOM, WHO Gr 3-4) is a common and debilitating side effect of intensity-modulated radiation therapy (IMRT) and concurrent cisplatin (CRT) in patients with head and neck cancer (HNC). Patient SOM burden is defined by multiple endpoints (incidence, duration, severity and time to onset) and it is critical to consider all in a “holistic” approach rather than a single endpoint. Generalized pairwise comparisons (GPC) statistical method allows combined assessment, while accounting for testing multiplicity. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: C.M. Anderson, S. Salvaggio, M. De Backer, J.C. Chiem, G.V. Walker, D. Saunders, C.M. Lee, N.E. Dunlap, E. Kennedy, B. Schoen, R. Beardsley, M. Buyse Tags: 226 Source Type: research

Phase II Trial of Quality-of-Life Outcomes after Proton Beam for Nasopharyngeal Carcinoma
Radiotherapy is a primary treatment modality for nasopharyngeal cancer (NPC). Advances in radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) have shown less detriment in quality of life (QOL). Proton beam therapy (PBT) has potential to further reduce detriment in QOL due to reduced exposure of normal tissues to low-dose radiation. The purpose of this study was to assess patient-reported QOL outcomes after PBT. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J. Slater, E.A. Weyman, A.W. Chan Tags: 190 Source Type: research

A Pilot Study of HNC Patients Treated Daily with an Intraoral Photobiomodulation (PBM) Device While Undergoing IMRT Demonstrates Tolerability, Safety, and Preliminary Efficacy for Reducing the Impact of Oral Mucositis
Oral mucositis (OM) is a significant AE and can impact cancer treatment (interruptions and/or early termination), increase opioid usage, impact diet (dysgeusia, dysphagia, inadequate nutritional intake), instigate depression and cause sepsis and death. Pharmacological options are limited; however supportive care treatment guidelines (MASCC, WALT) recommend intraoral photobiomodulation therapy (IOPBMT) for the prevention/treatment of OM. Photobiomodulation (PBM) is the use of non-ionizing light in the visible and near-infrared light spectra to modulate biological processes, such as promoting wound healing. (Source: Internat...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: M. Marotta, C. Holtzapfel, P.H. Shah, K.S. Hu, J.L. Frustino, C.D. Willey, C.M. McCluskey, S. Valentin, D. Ludlow, J. Lazzara, V. Kothari, N. Lipko Tags: 167 Source Type: research

Subgroup Analysis of the Benefit of Avasopasem Manganese on the Incidence, Severity, Duration and Onset of Severe Oral Mucositis in ROMAN Phase 3 Trial
IMRT plus cisplatin is established treatment for LAHNC, but ∼70% of patients develop severe oral mucositis (SOM; WHO grade 3 or 4), limiting their ability to eat solids (gr 3) or liquids (gr 4), and often requiring feeding tube nutrition. Radiotherapy (RT)-induced bursts of superoxide initiate SOM (Sonis 2004). Avasopasem (AVA) is an investigational small molecule selective dismutase mimetic converting superoxide to hydrogen peroxide, which may protect normal cells from, and potentially sensitize cancer cells to, RT (Anderson 2019, Sishc 2021). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: G.V. Walker, C.M. Lee, J.R. Kelley, N.E. Dunlap, V. Bar-Ad, D.A. Miller, V. King, A. Peddada, D. Ciuba, F. Vincent, B.C. Muzyka, A.L. Gillespie-Twardy, S. Sonis, J. Holmlund, D. Saunders, R. Beardsley, C.M. Anderson Tags: 166 Source Type: research

PD-1 inhibition combined with intensity-modulated radiotherapy, to better serve patients with retroperitoneal lymph node metastases from gastrointestinal cancer
CONCLUSIONS: PD-1 inhibitors plus IMRT may be a better method for advanced GI cancer patients with RPLN metastases. HBV-positive patients can benefit from either PD-1 inhibitors alone or in combination with IMRT.PMID:38482227 | PMC:PMC10932682 | DOI:10.21037/jgo-23-1011 (Source: Cancer Control)
Source: Cancer Control - March 14, 2024 Category: Cancer & Oncology Authors: Yunyun Lu Zhengxuying Fang Linglong Tao Michael D Chuong Yi Lu Source Type: research

Volumetric response and survival of patients with bulky idh-mutated grade 3 glioma managed with fet-fdg guided integrated boost imrt.
This study audits volumetric response, survival and functional outcomes in this ‘large volume’ subgroup who undergo intensity modulated radiation therapy (IMRT). (Source: Clinical Oncology)
Source: Clinical Oncology - March 12, 2024 Category: Radiology Authors: D. Mills, P. Horsley, V. Venkatasha, M. Back Tags: Original Article Source Type: research

Osteonecrosis of the jaw after radiation followed by bevacizumab
Osteonecrosis of the jaw is a recognized complication associated with bevacizumab. Here, we present a patient with squamous cell carcinoma of the tonsil who experienced minimal skin fibrosis following intensity-modulated radiation therapy. Subsequently, the patient developed rectal adenocarcinoma and encountered osteonecrosis of the jaw after receiving two cycles of bevacizumab. Close monitoring, accompanied by thorough examination to detect early signs of osteonecrosis of the jaw, should be considered for patients who have undergone radiation therapy in the head and neck region and are receiving bevacizumab or other medic...
Source: Dermatology Online Journal - March 12, 2024 Category: Dermatology Authors: Park, Lily Source Type: research

Deletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non ‐metastatic stage T4 nasopharyngeal carcinoma in IMRT era
ConclusionThe survival outcomes of treating T4 NPC IMRT combined by induction chemotherapy deleting concurrent chemotherapy with or without adjuvant chemotherapy are encouraging. Moreover, mucosal reaction, nausea, and vomiting reaction were reduced during IMRT. (Source: Cancer Medicine)
Source: Cancer Medicine - March 8, 2024 Category: Cancer & Oncology Authors: Yuming Zheng, Fen Xue, Dan Ou, Xiaoshuang Niu, Chaosu Hu, Xiayun He Tags: RESEARCH ARTICLE Source Type: research

Anatomical changes and dosimetric analysis of the neck region based on FBCT for nasopharyngeal carcinoma patients during radiotherapy
CONCLUSION: Significant anatomic and dosimetric changes were observed in the target volumes and OARs. Based on the identified thresholds, replanning at approximately 20 fractions is crucial to ensure adequate target volumes dose and avoid overdosing to the OARs. This approach is clinically feasible and strongly recommended, particularly for centers without access to an adaptive planning system.PMID:38457140 | DOI:10.3233/XST-230280 (Source: Journal of X-Ray Science and Technology)
Source: Journal of X-Ray Science and Technology - March 8, 2024 Category: Radiology Authors: Aoqiang Chen Xuemei Chen Xiaobo Jiang Yajuan Wang Feng Chi Dehuan Xie Meijuan Zhou Source Type: research

Predicting the error magnitude in patient-specific QA during radiotherapy based on ResNet
CONCLUSIONS: In this study, error magnitude prediction models with dose difference, gamma distribution, and RDD + EDD are established based on ResNet. The accurate prediction of the error magnitude under different error types can provide reference for error analysis in patient-specific QA.PMID:38457139 | DOI:10.3233/XST-230251 (Source: Journal of X-Ray Science and Technology)
Source: Journal of X-Ray Science and Technology - March 8, 2024 Category: Radiology Authors: Ying Huang Yifei Pi Kui Ma Xiaojuan Miao Sichao Fu Aihui Feng Duan Yanhua Qing Kong Weihai Zhuo Zhiyong Xu Source Type: research